GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (OCSE:HLUN B) » Definitions » Cyclically Adjusted PB Ratio

H. Lundbeck AS (OCSE:HLUN B) Cyclically Adjusted PB Ratio : 0.48 (As of Jun. 05, 2025)


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Cyclically Adjusted PB Ratio?

As of today (2025-06-05), H. Lundbeck AS's current share price is kr36.98. H. Lundbeck AS's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 was kr76.52. H. Lundbeck AS's Cyclically Adjusted PB Ratio for today is 0.48.

The historical rank and industry rank for H. Lundbeck AS's Cyclically Adjusted PB Ratio or its related term are showing as below:

OCSE:HLUN B' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.31   Med: 0.46   Max: 0.64
Current: 0.49

During the past years, H. Lundbeck AS's highest Cyclically Adjusted PB Ratio was 0.64. The lowest was 0.31. And the median was 0.46.

OCSE:HLUN B's Cyclically Adjusted PB Ratio is ranked better than
87.64% of 696 companies
in the Drug Manufacturers industry
Industry Median: 1.975 vs OCSE:HLUN B: 0.49

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

H. Lundbeck AS's adjusted book value per share data for the three months ended in Dec. 2024 was kr25.231. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr76.52 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


H. Lundbeck AS Cyclically Adjusted PB Ratio Historical Data

The historical data trend for H. Lundbeck AS's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS Cyclically Adjusted PB Ratio Chart

H. Lundbeck AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.33 0.43 0.54

H. Lundbeck AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.43 0.52 0.58 0.54

Competitive Comparison of H. Lundbeck AS's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


H. Lundbeck AS's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's Cyclically Adjusted PB Ratio falls into.


;
;

H. Lundbeck AS Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

H. Lundbeck AS's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=36.98/76.52
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

H. Lundbeck AS's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, H. Lundbeck AS's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book=Book Value per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=25.231/118.9000*118.9000
=25.231

Current CPI (Dec. 2024) = 118.9000.

H. Lundbeck AS Quarterly Data

Book Value per Share CPI Adj_Book
201503 72.866 100.200 86.465
201506 51.861 100.300 61.478
201509 45.590 100.200 54.098
201512 44.526 99.800 53.048
201603 44.262 100.200 52.522
201606 44.916 100.600 53.087
201609 46.410 100.200 55.071
201612 49.121 100.300 58.230
201703 49.765 101.200 58.469
201706 53.762 101.200 63.165
201709 58.035 101.800 67.784
201712 61.316 101.300 71.969
201803 58.441 101.700 68.325
201806 63.079 102.300 73.315
201809 67.984 102.400 78.938
201812 71.707 102.100 83.506
201903 63.997 102.900 73.948
201906 67.907 102.900 78.466
201909 72.305 102.900 83.548
201912 84.458 102.900 97.590
202003 70.826 103.300 81.522
202006 72.929 103.200 84.024
202009 73.856 103.500 84.845
202012 85.421 103.400 98.226
202103 86.679 104.300 98.812
202106 88.275 105.000 99.961
202109 91.031 105.800 102.302
202112 92.018 106.600 102.635
202203 92.895 109.900 100.502
202206 19.737 113.600 20.658
202209 21.070 116.400 21.523
202212 20.929 115.900 21.471
202303 21.131 117.300 21.419
202306 21.728 116.400 22.195
202309 22.485 117.400 22.772
202312 22.223 116.700 22.642
202403 22.616 118.400 22.712
202406 23.409 118.500 23.488
202409 24.047 118.900 24.047
202412 25.231 118.900 25.231

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


H. Lundbeck AS  (OCSE:HLUN B) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


H. Lundbeck AS Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


H. Lundbeck AS Business Description

Address
Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS Headlines

No Headlines